{"gene":"INPP4B","run_date":"2026-06-10T01:55:23","timeline":{"discoveries":[{"year":2006,"finding":"INPP4B protein contains a consensus phosphatase catalytic site and a C2 domain; the C2 domain interacts preferentially with phosphatidic acid and PI(3,4,5)P3 lipids. Two isoforms exist: Inpp4bα is mainly cytosolic, while Inpp4bβ localizes to the Golgi apparatus, suggesting distinct cellular functions for each isoform.","method":"cDNA isolation, domain characterization, lipid-binding assay (C2 domain binding to lipid panels), subcellular localization by fractionation/imaging","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct lipid-binding assay and subcellular fractionation/localization in a single focused study with multiple methods","pmids":["16631325"],"is_preprint":false},{"year":2011,"finding":"INPP4B dephosphorylates phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2), leading to reduced Akt phosphorylation and activity. In prostate cancer cells, androgen receptor (AR) induces INPP4B expression (but not PTEN), and this induction requires the transcriptional coactivator NCoR. INPP4B depletion activated Akt and increased cellular proliferation.","method":"siRNA knockdown, Western blot for p-Akt, reporter/expression assays for AR-mediated induction, NCoR co-activator studies","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined signaling readout and transcriptional mechanism, single lab with multiple orthogonal methods","pmids":["21224358"],"is_preprint":false},{"year":2013,"finding":"INPP4B has protein tyrosine phosphatase (PTP) activity in addition to lipid phosphatase activity, demonstrated by dephosphorylation of synthetic phosphotyrosine analogs (pNPP and DiFMUP). Mutagenesis of the catalytic site (CX5R motif, C842KSAKDR): K843M increased pNPP hydrolysis; K846M abolished lipid phosphatase activity without affecting PTP activity; D847E ablated PTP activity and significantly reduced lipid phosphatase activity. INPP4B, but not PTEN, reduced tyrosine phosphorylation of Akt1, with both lipid and protein phosphatase activities contributing.","method":"In vitro phosphatase assays (pNPP, DiFMUP), site-directed mutagenesis of catalytic residues, Western blot for Akt1 tyrosine phosphorylation","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic assay combined with systematic active-site mutagenesis identifying distinct residues for lipid vs. protein phosphatase activities","pmids":["24070612"],"is_preprint":false},{"year":2014,"finding":"SGK3 is activated downstream of PIK3CA in a manner dependent on INPP4B. INPP4B expression enhances SGK3 activation while suppressing Akt phosphorylation. SGK3 activation downstream of PIK3CA/INPP4B is required for 3D proliferation, invasive migration, and tumorigenesis in vivo. SGK3 targets the metastasis suppressor NDRG1 for degradation by Fbw7.","method":"Overexpression and knockdown studies, in vitro 3D proliferation and invasion assays, in vivo tumorigenesis, Western blot for p-SGK3 and p-Akt","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal gain/loss-of-function, multiple orthogonal functional assays (3D proliferation, invasion, in vivo), mechanistic pathway placement; replicated in multiple subsequent studies","pmids":["25458846"],"is_preprint":false},{"year":2015,"finding":"INPP4B is enriched at early endosomes in thyroid cancer cells, where it selectively inhibits AKT2 (but not AKT1) activation, suppressing tumor proliferation and anchorage-independent growth. INPP4B and PTEN do not act epistatically in thyroid oncogenesis; combined heterozygous Pten loss and Inpp4b deletion in mice produces lethal metastatic follicular thyroid cancer, while single knockouts do not.","method":"Subcellular fractionation/immunofluorescence (endosome localization), genetic mouse models (Pten+/- × Inpp4b-/-), isoform-specific Akt activation assays, 3D growth assays","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic epistasis in mouse models combined with subcellular localization and isoform-specific AKT activation assays in a single rigorous study","pmids":["25883022"],"is_preprint":false},{"year":2015,"finding":"INPP4B directly dephosphorylates PtdIns(3,4,5)P3 (PIP3) in vitro, acting as a PIP3 3-phosphatase. In vivo, combined Inpp4b deletion and Pten heterozygosity synergistically increases PtdIns(3,4,5)P3 levels and activates downstream AKT signaling in thyroid cells, inducing malignant thyroid cancer with lung metastases.","method":"In vitro phosphatase assay (direct PIP3 dephosphorylation), mouse genetic models (Inpp4bΔ/Δ and Pten+/-), phosphoinositide mass measurement","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro biochemical assay demonstrating PIP3 phosphatase activity combined with in vivo genetic model; independent replication of thyroid cancer phenotype across two concurrent papers","pmids":["25883023"],"is_preprint":false},{"year":2015,"finding":"Loss of INPP4B causes a DNA repair defect associated with reduced BRCA1, ATM, and ATR protein stability. INPP4B forms a protein complex with ATR and BRCA1 (demonstrated by GST pulldown and 293T overexpression assays). INPP4B-deficient cells show increased sensitivity to PARP inhibitors comparable to BRCA1 loss, both in vitro and in vivo xenograft models.","method":"GST pulldown, co-overexpression assays in 293T cells, comet assay, γH2AX/RAD51/53BP1 foci quantification, PARP inhibitor sensitivity assays in 2D/3D culture and xenografts","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — protein-protein interaction by GST pulldown and overexpression Co-IP, combined with functional DNA repair assays, single lab","pmids":["25868852"],"is_preprint":false},{"year":2015,"finding":"In AML, INPP4B overexpression confers leukemic resistance to chemotherapy (cytosine arabinoside, daunorubicin, etoposide) through a phosphatase-dependent but Akt-independent mechanism; expression of the phosphatase-dead INPP4B C842A variant failed to confer resistance in vitro or in vivo.","method":"Ectopic overexpression of wild-type vs. phosphatase-dead (C842A) INPP4B, in vitro drug resistance assays, in vivo xenograft chemotherapy resistance, siRNA knockdown","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — catalytic mutant comparison in vitro and in vivo establishes phosphatase-dependent resistance mechanism, single lab","pmids":["25736313"],"is_preprint":false},{"year":2015,"finding":"In colon cancer cells, INPP4B upregulation is driven by Ets-1-mediated transcriptional activation. INPP4B promotes Akt and SGK3 activation in colon cancer and this is associated with inactivation of PTEN through its protein phosphatase activity. INPP4B silencing blocks Akt and SGK3 activation and inhibits colon cancer cell proliferation and xenograft growth.","method":"Ets-1 promoter activity assays, siRNA knockdown, overexpression studies, Western blot for p-Akt/p-SGK3, xenograft growth assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptional mechanism identified with functional follow-up, single lab with multiple methods","pmids":["26411369"],"is_preprint":false},{"year":2013,"finding":"INPP4B-mediated resistance to irradiation in laryngeal cancer cells is associated with increased aerobic glycolysis. INPP4B overexpression enhances aerobic glycolysis through upregulation of hexokinase 2 (HK2), mediated via the Akt-mTOR pathway. Co-depletion of INPP4B and HK2 sensitizes radioresistant cells to irradiation and anticancer drugs.","method":"INPP4B overexpression/knockdown, glycolysis measurement, HK2 expression analysis, Akt-mTOR pathway inhibitor experiments, co-depletion assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway epistasis via pharmacological inhibition and co-depletion studies, single lab","pmids":["24051093"],"is_preprint":false},{"year":2014,"finding":"INPP4B suppresses prostate cancer cell invasion in vitro and in vivo. Mechanistically, INPP4B suppresses oncogenic PKC signaling independently of the PI3K/Akt pathway, as PI3K/Akt inhibition did not reproduce INPP4B-mediated suppression of IL-8 but PKC inhibition did. INPP4B reduces phosphorylation of PKC, expression of BIRC5, and downstream target COX-2.","method":"De novo INPP4B expression in invasive PC-3 cells, in vitro invasion assays, in vivo invasion assay, global gene expression analysis, PI3K/Akt and PKC pathway inhibitor comparisons","journal":"Cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological epistasis distinguishing PKC from PI3K/Akt as INPP4B effector pathway, single lab with multiple methods","pmids":["25248616"],"is_preprint":false},{"year":2020,"finding":"INPP4B localizes to late endosomes via interaction with Rab7 in PIK3CA-mutant ER+ breast cancer cells. This endosomal localization drives PI3Kα-dependent conversion of PI(3,4)P2 to PI(3)P on late endosomes, increasing late endosome/lysosome number and cargo trafficking, resulting in GSK3β lysosomal degradation and activation of Wnt/β-catenin signaling. INPP4B-mediated proliferation requires the PI(3)P-effector Hrs, and Wnt inhibition blocks INPP4B-driven tumor growth.","method":"Integrated proteomics/transcriptomics/imaging, Rab7 interaction assay, phosphoinositide measurement, lysosome number quantification, GSK3β degradation assay, Wnt pathway reporter assays, Hrs depletion rescue experiments, in vivo tumor growth","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (proteomics, imaging, phosphoinositide quantification, in vivo), Rab7 interaction established, downstream mechanism validated with genetic rescue in a single rigorous study","pmids":["34035258"],"is_preprint":false},{"year":2020,"finding":"INPP4B deficiency increases PI(3,4)P2 levels specifically in endocytic vesicles (not at the plasma membrane), delays EGFR and MET lysosomal degradation while promoting their recycling, thus enhancing RTK signaling duration and amplitude upon growth factor stimulation. Loss of INPP4B in TNBC increases both AKT and MEK/ERK pathway activation.","method":"INPP4B knockout mouse model (genetically engineered TNBC), phosphoinositide localization assays, EGFR/MET trafficking assays (pulse-chase, receptor recycling/degradation), PI3K and MEK inhibitor sensitivity in vivo","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetically engineered mouse model plus mechanistic RTK trafficking experiments with phosphoinositide localization, multiple orthogonal methods","pmids":["32513774"],"is_preprint":false},{"year":2020,"finding":"INPP4B is required for TGFβ receptor endocytosis. Specifically, INPP4B (the 4'-phosphatase), together with synaptojanin1 and PI3K-C2α, mediates sequential phosphoinositide conversions essential for TGFβ-induced endocytosis of TGFβ receptor, Smad2 and Smad3 activation. INPP4B knockdown abolished these signaling events.","method":"siRNA-mediated knockdown of INPP4B and pathway components, live-cell phosphoinositide imaging at the plasma membrane, TGFβ receptor endocytosis assays, Smad2/3 phosphorylation assays","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — specific knockdown with defined molecular readouts (phosphoinositide dynamics, receptor endocytosis, Smad signaling), single lab","pmids":["31913757"],"is_preprint":false},{"year":2017,"finding":"In PTEN-null TNBC cells, INPP4B loss decreases basal p-Akt and proliferation. Accumulated PI(3,4)P2 (when both PTEN and INPP4B are lost) acts as an inhibitory second messenger toward PI3K, revealing a negative feedback mechanism. INPP4B overexpression desensitizes cells to PI3K inhibitors in a phosphatase activity-dependent manner.","method":"siRNA knockdown and overexpression of INPP4B in PTEN-null TNBC lines, phospho-Akt Western blot, PI3K isoform-selective inhibitor sensitivity assays","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphatase-activity dependence established, multiple TNBC cell lines, single lab","pmids":["28196852"],"is_preprint":false},{"year":2018,"finding":"In NPM1-mutated AML cells, INPP4B promotes cell survival through SGK3 activation without affecting Akt. INPP4B overexpression increases PI(3,4)P2 to PI(3)P conversion (measured by ELISA), and SGK3 knockdown abrogates INPP4B-induced proliferation. High INPP4B levels in NPM1-mutated AML are caused at least partly by the NPM1 mutant acting through ERK/Ets-1 signaling.","method":"INPP4B overexpression/knockdown, SGK3 knockdown rescue assay, PI(3,4)P2 and PI(3)P ELISA, ERK/Ets-1 pathway analysis, colony formation and proliferation assays","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphoinositide mass measurement plus SGK3 rescue epistasis in a single lab, multiple orthogonal methods","pmids":["29343273"],"is_preprint":false},{"year":2016,"finding":"In AML, INPP4B-mediated chemoresistance involves enhanced ATM-dependent DNA repair. INPP4B knockdown reduces ATM expression and downstream p-ATM, p-BRCA1, p-ATR, and p-RAD51 activation, as well as nuclear p65 localization. Re-activation of p65 rescues ATM pathway activity after INPP4B knockdown, placing NF-κB (p65) between INPP4B and ATM in the DNA repair pathway.","method":"INPP4B knockdown, γH2AX assay, Western blot for ATM/p-ATM/p-BRCA1/p-ATR/p-RAD51, NF-κB p65 nuclear localization assay, p65 rescue experiments, cytarabine sensitivity assays","journal":"Tumour biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway epistasis via p65 rescue experiments, multiple DNA repair markers, single lab","pmids":["27342972"],"is_preprint":false},{"year":2017,"finding":"IRF2 binds the INPP4B promoter and transcriptionally activates INPP4B expression in AML cells, placing IRF2 upstream of INPP4B in a signaling axis regulating AML cell growth and apoptosis. Restoration of INPP4B expression rescues the effects of IRF2 knockdown on apoptosis and colony formation.","method":"IRF2 promoter binding (ChIP-like assay implied), INPP4B rescue after IRF2 knockdown, colony formation and apoptosis assays in AML cell lines","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptional regulatory relationship established with functional rescue, single lab","pmids":["28579269"],"is_preprint":false},{"year":2021,"finding":"INPP4B suppresses AKT and PKC signaling in the liver to improve insulin sensitivity. Loss of INPP4B leads to proteolytic cleavage and activation of SREBP1, a key regulator of de novo lipogenesis, driving upregulation of PPARG and lipogenic pathways. Inpp4b-/- mice on a high fat diet develop obesity, NAFLD, type II diabetes, and prostatic intraepithelial neoplasia driven by inflammation.","method":"Inpp4b knockout mice, high fat diet model, AKT/PKC phosphorylation assays, SREBP1 cleavage analysis by Western blot, metabolic phenotyping (energy expenditure, respiratory exchange ratio), histology","journal":"Communications biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knockout model with multiple orthogonal mechanistic readouts (SREBP1 cleavage, AKT/PKC signaling, metabolic parameters), single lab rigorous study","pmids":["33772116"],"is_preprint":false},{"year":2022,"finding":"INPP4B (Inpp4b) is required for normal lysosomal homeostasis and dynamics. In Inpp4b-deficient mouse embryonic fibroblasts, inhibition of PIKfyve causes massively enlarged lysosomes, disrupted lysosome fusion-fission dynamics, and impaired autophagy. Mechanistically, Inpp4b deficiency causes hyperactivation of VPS34 (PI3K class III), elevating lysosomal PtdIns(3)P levels, which is exacerbated when PIKfyve is inhibited.","method":"Inpp4b-deficient MEFs, PIKfyve inhibitor treatment, confocal fluorescence imaging of lysosomes, HPLC scintillation quantification of 3H-myo-inositol labeled PtdIns, PtdIns immunofluorescence, VPS34 activity assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct phosphoinositide quantification plus enzymatic activity assay in genetic model, multiple orthogonal methods in a single rigorous study","pmids":["35760104"],"is_preprint":false},{"year":2024,"finding":"INPP4B is a hallmark feature of tissue-resident ILC1s and intratumoral NK cells. Conditional deletion of Inpp4b in ILC1s and NK cells reduces tissue-resident ILC1 homeostasis (but not circulating NK cells) at steady state through increased apoptosis and reduced AKT activation. INPP4B expression is necessary for ILC1/NK cell presence in the intratumoral environment and for antitumor immunity.","method":"scRNA-seq atlas, conditional Inpp4b knockout mice, flow cytometry (apoptosis, cell numbers), AKT phosphorylation assays, intratumoral NK/ILC1 quantification, tumor growth assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional knockout in specific cell types with multiple orthogonal functional readouts (apoptosis, AKT activation, tumor immunity), in vivo","pmids":["38197946"],"is_preprint":false},{"year":2023,"finding":"Loss of INPP4B (but not PTEN) in prostate cells decreases EZH2 expression and reduces H3 methylation levels. INPP4B and EZH2 are positively correlated in normal prostate and early-stage tumors (unlike PTEN, which is inversely correlated with EZH2). INPP4B loss elevates p53 protein expression and Akt phosphorylation in murine prostates, but unlike PTEN loss does not affect SMAD4 protein or Pml mRNA.","method":"INPP4B knockdown in human prostate cancer cell lines, Inpp4b knockout mouse prostate analysis, Western blot for EZH2 and H3 methylation, single-cell transcriptomic analysis","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro knockdown plus in vivo mouse model demonstrating distinct downstream effectors vs. PTEN, single lab","pmids":["38001678"],"is_preprint":false},{"year":2020,"finding":"Estrogen receptor β1 (ERβ1) induces INPP4B expression in prostate cancer cells in response to ERβ ligands, leading to inhibition of Akt activity and reduction in cell migration, providing a mechanism for androgen-independent regulation of INPP4B.","method":"ERβ1 expression engineering in PC3 cells, ERβ ligand treatment, Western blot for INPP4B and p-Akt, cell migration assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function with defined molecular and functional readouts, single lab","pmids":["33020300"],"is_preprint":false},{"year":2025,"finding":"INPP4B promotes fibronectin 1 (FN1) secretion via TRPML1 (transient receptor potential cation channel mucolipin subfamily member 1)-dependent lysosomal exocytosis in pancreatic ductal adenocarcinoma. INPP4B-mediated regulation of F-actin formation, focal adhesion kinase activation, and increased cell migration and invasion depend on FN1 exocytosis.","method":"INPP4B overexpression/knockdown in PDAC cells, FN1 secretion assay, TRPML1 inhibitor/knockdown, F-actin staining, FAK phosphorylation Western blot, migration and invasion assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays with pathway dissection (TRPML1-FN1 axis), single lab","pmids":["40962057"],"is_preprint":false},{"year":2023,"finding":"Inpp4b is required for normal B-1 cell numbers and B cell-mediated antibody production. Inpp4b deficiency intrinsically reduces peritoneal B-1 cells (but not B-2 cells) and impairs thymus-independent and thymus-dependent antigen-induced antibody production. CD40-mediated B cell proliferation is impaired upon Inpp4b ablation.","method":"Inpp4b conventional knockout mice, adoptive transfer studies, flow cytometry phenotyping, in vitro B cell activation and proliferation assays (CD40-mediated)","journal":"Scandinavian journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with adoptive transfer epistasis and in vitro functional assays, single lab","pmids":["37389566"],"is_preprint":false},{"year":2019,"finding":"Inpp4b deficiency cooperates with SV40 T-Large antigen to promote cellular transformation in mouse embryonic fibroblasts, associated with increased phosphorylated-Akt levels. INPP4B overexpression in SV40 T-Large MEFs dampens transformation and reduces p-Akt. Inpp4b deficiency or overexpression was insufficient to induce transformation alone or in combination with H-Ras or E1A.","method":"MEF transformation assay with Inpp4b knockout and overexpression, SV40 T-Large/H-Ras/E1A co-expression, p-Akt Western blot","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in MEF transformation model, multiple oncogene combinations tested, single lab","pmids":["31695845"],"is_preprint":false}],"current_model":"INPP4B is a dual-specificity phosphoinositide phosphatase that hydrolyzes both PI(3,4)P2 (to PI(3)P) and PtdIns(3,4,5)P3 (to PtdIns(3,4)P2) to negatively regulate PI3K/AKT signaling; it also possesses protein tyrosine phosphatase activity and its precise oncogenic vs. tumor-suppressive output is context-dependent, determined by subcellular localization (cytosol, early or late endosomes, Golgi), cell type, and co-occurring mutations—with endosomal INPP4B generating PI(3)P to activate SGK3 and Wnt/β-catenin signaling in certain cancers, while cytosolic INPP4B degrades PI(3,4)P2 to suppress AKT in others; additionally, INPP4B regulates RTK trafficking, TGFβ receptor endocytosis, lysosomal homeostasis via VPS34, DNA repair through a BRCA1/ATM/ATR complex, metabolic signaling via SREBP1 cleavage in the liver, and innate immune cell survival through AKT-dependent mechanisms in tissue-resident ILC1s."},"narrative":{"mechanistic_narrative":"INPP4B is a dual-specificity phosphoinositide phosphatase whose principal biochemical activity is hydrolysis of PI(3,4)P2 to PI(3)P, with additional direct PtdIns(3,4,5)P3 3-phosphatase activity and an intrinsic protein tyrosine phosphatase activity—the lipid and protein phosphatase functions being separable through distinct catalytic-site residues (K846 for lipid, D847 for protein activity) [PMID:24070612, PMID:25883023]. Through these activities it negatively regulates PI3K/AKT signaling, and combined loss of Inpp4b and Pten synergistically elevates PtdIns(3,4,5)P3 and AKT activation to drive metastatic thyroid cancer, establishing INPP4B as a tumor suppressor that acts non-epistatically with PTEN [PMID:25883022, PMID:25883023]. Its functional output is governed by subcellular localization: at late endosomes, Rab7-dependent INPP4B converts PI(3,4)P2 to PI(3)P to drive lysosomal GSK3β degradation and Wnt/β-catenin signaling, and the same PI(3,4)P2-to-PI(3)P conversion activates SGK3 (downstream of PIK3CA) to promote proliferation, invasion, and tumorigenesis in a manner independent of AKT [PMID:25458846, PMID:34035258, PMID:29343273]. INPP4B controls endosomal phosphoinositide pools that regulate receptor trafficking—restraining EGFR/MET recycling and signaling duration and enabling TGFβ receptor endocytosis and Smad2/3 activation—and maintains lysosomal homeostasis and autophagy by limiting VPS34-driven lysosomal PtdIns(3)P [PMID:32513774, PMID:31913757, PMID:35760104]. Beyond cancer cell signaling, INPP4B suppresses hepatic AKT/PKC signaling and SREBP1 cleavage to maintain insulin sensitivity and restrain lipogenesis, and supports AKT-dependent survival of tissue-resident ILC1s and B-1 cells [PMID:33772116, PMID:38197946, PMID:37389566]. Its expression is transcriptionally controlled in a context-specific manner by androgen receptor/NCoR, ERβ1, Ets-1, and IRF2 [PMID:21224358, PMID:26411369, PMID:28579269, PMID:33020300].","teleology":[{"year":2006,"claim":"Established INPP4B's domain architecture and isoform-specific localization, framing it as a lipid-interacting phosphatase with potentially distinct cytosolic versus Golgi functions.","evidence":"cDNA isolation, C2-domain lipid-binding assays, and subcellular fractionation/imaging of two isoforms","pmids":["16631325"],"confidence":"Medium","gaps":["Catalytic substrate not directly demonstrated in this study","Functional consequence of isoform localization untested"]},{"year":2011,"claim":"Demonstrated that INPP4B dephosphorylates PI(3,4)P2 to suppress AKT and proliferation, and that androgen receptor/NCoR drives its expression, positioning it as a PI3K/AKT tumor suppressor.","evidence":"siRNA knockdown with p-Akt Western blot and AR/NCoR transcriptional induction assays in prostate cancer cells","pmids":["21224358"],"confidence":"Medium","gaps":["Did not address direct PIP3 hydrolysis","In vivo tumor suppression not tested here"]},{"year":2013,"claim":"Resolved that INPP4B carries separable lipid and protein tyrosine phosphatase activities through distinct active-site residues, expanding its enzymatic repertoire beyond a single lipid substrate.","evidence":"In vitro pNPP/DiFMUP assays with systematic CX5R-motif mutagenesis and Akt1 tyrosine-phosphorylation readout","pmids":["24070612"],"confidence":"High","gaps":["Physiological protein substrates of the PTP activity not identified","Relative cellular contribution of each activity unquantified"]},{"year":2013,"claim":"Linked INPP4B to metabolic reprogramming, showing it can promote aerobic glycolysis and radioresistance via Akt-mTOR-driven HK2, an early sign of context-dependent oncogenic output.","evidence":"Overexpression/knockdown, glycolysis and HK2 measurement, pathway inhibitor and co-depletion experiments in laryngeal cancer cells","pmids":["24051093"],"confidence":"Medium","gaps":["Mechanism reconciling AKT suppression vs Akt-mTOR-HK2 activation unclear","Single cancer context"]},{"year":2014,"claim":"Identified SGK3 as an AKT-independent effector of INPP4B, explaining how INPP4B can promote proliferation, invasion, and tumorigenesis while suppressing AKT.","evidence":"Reciprocal gain/loss-of-function, 3D proliferation/invasion assays, in vivo tumorigenesis, and p-SGK3/NDRG1 readouts","pmids":["25458846"],"confidence":"High","gaps":["Lipid product (PI(3)P) driving SGK3 not directly measured here","Subcellular site of SGK3 activation not defined"]},{"year":2014,"claim":"Showed INPP4B can suppress invasion through PKC rather than PI3K/Akt, broadening its effector landscape beyond phosphoinositide-AKT signaling.","evidence":"De novo expression in PC-3 cells, invasion assays, gene expression profiling, and PKC vs PI3K/Akt inhibitor comparisons","pmids":["25248616"],"confidence":"Medium","gaps":["Direct biochemical link between INPP4B and PKC not established","Whether effect depends on lipid or protein phosphatase activity untested"]},{"year":2015,"claim":"Established INPP4B as a bona fide tumor suppressor with direct PIP3 3-phosphatase activity that acts non-epistatically with PTEN in vivo.","evidence":"Two concurrent studies: direct in vitro PIP3 dephosphorylation, endosomal localization, isoform-specific AKT2 inhibition, and Pten+/-×Inpp4b-/- mouse thyroid cancer models","pmids":["25883022","25883023"],"confidence":"High","gaps":["Relative in vivo contribution of PI(3,4)P2 vs PIP3 hydrolysis unresolved","Why AKT2 but not AKT1 is targeted mechanistically unclear"]},{"year":2015,"claim":"Implicated INPP4B in DNA repair by showing it stabilizes a BRCA1/ATM/ATR complex and confers PARP-inhibitor sensitivity when lost.","evidence":"GST pulldown and 293T co-overexpression, comet/γH2AX/RAD51/53BP1 foci, and PARP inhibitor sensitivity in xenografts","pmids":["25868852"],"confidence":"Medium","gaps":["Interaction shown by overexpression Co-IP without reciprocal endogenous validation","Mechanism by which a phosphatase stabilizes repair proteins unknown"]},{"year":2015,"claim":"Revealed an oncogenic, phosphatase-dependent but Akt-independent role for INPP4B in conferring AML chemoresistance, formalizing its context-dependent duality.","evidence":"Wild-type vs phosphatase-dead C842A overexpression in drug resistance assays in vitro and in xenografts","pmids":["25736313"],"confidence":"Medium","gaps":["Downstream effector of the Akt-independent resistance not defined here","Relevant phosphoinositide product not measured"]},{"year":2015,"claim":"Showed Ets-1-driven INPP4B promotes Akt and SGK3 activation in colon cancer, reinforcing transcriptional control and the SGK3 oncogenic axis.","evidence":"Ets-1 promoter assays, knockdown/overexpression, p-Akt/p-SGK3 Westerns, and xenograft growth","pmids":["26411369"],"confidence":"Medium","gaps":["Claimed PTEN inactivation via protein phosphatase activity not biochemically demonstrated","Direct substrate undefined"]},{"year":2016,"claim":"Connected INPP4B chemoresistance in AML to ATM-dependent DNA repair via an NF-κB(p65)-to-ATM relay, linking the resistance and DNA-repair phenotypes.","evidence":"Knockdown with DNA-repair marker Westerns, p65 nuclear localization, and p65 rescue experiments","pmids":["27342972"],"confidence":"Medium","gaps":["How INPP4B phosphatase activity regulates p65 not established","Single lab, correlative pathway placement"]},{"year":2017,"claim":"Uncovered a PI(3,4)P2 negative-feedback mechanism whereby accumulated PI(3,4)P2 inhibits PI3K and modulates PI3K-inhibitor sensitivity in PTEN-null TNBC.","evidence":"Knockdown/overexpression in PTEN-null TNBC lines with p-Akt Westerns and isoform-selective PI3K inhibitor assays","pmids":["28196852"],"confidence":"Medium","gaps":["Molecular target of the inhibitory PI(3,4)P2 signal not identified","Generalizability beyond PTEN-null context untested"]},{"year":2017,"claim":"Added IRF2 as an upstream transcriptional activator of INPP4B governing AML growth and apoptosis.","evidence":"IRF2 promoter binding, INPP4B rescue after IRF2 knockdown, colony formation and apoptosis assays","pmids":["28579269"],"confidence":"Medium","gaps":["Direct promoter occupancy via rigorous ChIP not detailed","Downstream INPP4B effector in this axis unspecified"]},{"year":2018,"claim":"Confirmed that endosomal PI(3,4)P2-to-PI(3)P conversion by INPP4B drives SGK3-dependent survival in NPM1-mutant AML independent of Akt.","evidence":"Overexpression/knockdown, SGK3 knockdown rescue, PI(3,4)P2/PI(3)P ELISA, and ERK/Ets-1 analysis","pmids":["29343273"],"confidence":"Medium","gaps":["Subcellular site of lipid conversion not imaged","How SGK3 promotes survival downstream not detailed"]},{"year":2019,"claim":"Demonstrated that Inpp4b loss cooperates with SV40 T-Large to promote transformation via elevated p-Akt, but is insufficient alone, defining it as a context-dependent suppressor.","evidence":"MEF transformation assays with Inpp4b knockout/overexpression across oncogene combinations and p-Akt Westerns","pmids":["31695845"],"confidence":"Medium","gaps":["Mechanism of cooperativity with T-Large not dissected","Specific lipid substrate change not measured"]},{"year":2020,"claim":"Defined the late-endosomal, Rab7-anchored pool of INPP4B that produces PI(3)P to drive lysosomal GSK3β degradation and oncogenic Wnt/β-catenin signaling in PIK3CA-mutant breast cancer.","evidence":"Integrated proteomics/imaging, Rab7 interaction, phosphoinositide measurement, GSK3β degradation, Wnt reporters, Hrs-depletion rescue, and in vivo growth","pmids":["34035258"],"confidence":"High","gaps":["Determinants of late- vs early-endosomal targeting incompletely defined","Generalizability beyond PIK3CA-mutant ER+ breast cancer untested"]},{"year":2020,"claim":"Showed INPP4B restrains endocytic PI(3,4)P2 to limit EGFR/MET recycling and signaling duration, with its loss amplifying both AKT and MEK/ERK in TNBC.","evidence":"INPP4B-knockout TNBC mouse model, phosphoinositide localization, RTK pulse-chase trafficking, and PI3K/MEK inhibitor sensitivity in vivo","pmids":["32513774"],"confidence":"High","gaps":["Direct adaptor linking INPP4B to specific RTK endosomes not identified","Whether protein phosphatase activity contributes unaddressed"]},{"year":2020,"claim":"Established that INPP4B is required for TGFβ receptor endocytosis and Smad2/3 activation through sequential phosphoinositide conversion with synaptojanin1 and PI3K-C2α.","evidence":"siRNA knockdown of pathway components, live-cell phosphoinositide imaging, receptor endocytosis and Smad phosphorylation assays","pmids":["31913757"],"confidence":"Medium","gaps":["Direct enzymatic ordering at the membrane inferred, not reconstituted","Single-lab knockdown evidence"]},{"year":2020,"claim":"Identified ERβ1 as an androgen-independent transcriptional inducer of INPP4B that suppresses Akt and migration in prostate cancer.","evidence":"ERβ1 engineering and ligand treatment in PC3 cells with INPP4B/p-Akt Westerns and migration assays","pmids":["33020300"],"confidence":"Medium","gaps":["Direct ERβ1 promoter binding not shown","In vivo relevance untested"]},{"year":2021,"claim":"Extended INPP4B function to whole-body metabolism, showing it suppresses hepatic AKT/PKC and SREBP1 cleavage to maintain insulin sensitivity and restrain lipogenesis.","evidence":"Inpp4b knockout mice on high-fat diet with SREBP1 cleavage analysis, AKT/PKC Westerns, metabolic phenotyping, and histology","pmids":["33772116"],"confidence":"High","gaps":["Mechanistic link between INPP4B and SREBP1 protease not defined","Tissue-specific contributions not separated"]},{"year":2022,"claim":"Revealed INPP4B's requirement for lysosomal homeostasis and autophagy by limiting VPS34-driven lysosomal PtdIns(3)P.","evidence":"Inpp4b-deficient MEFs with PIKfyve inhibition, lysosome imaging, HPLC PtdIns quantification, and VPS34 activity assays","pmids":["35760104"],"confidence":"High","gaps":["How INPP4B suppresses VPS34 activity mechanistically unclear","Relationship to its own PI(3)P-generating activity not reconciled"]},{"year":2023,"claim":"Showed INPP4B, distinct from PTEN, supports EZH2 expression and H3 methylation and engages a unique set of downstream effectors in prostate cells.","evidence":"Knockdown in prostate cancer lines and Inpp4b knockout mouse prostate analysis with EZH2/H3-methylation Westerns and scRNA-seq","pmids":["38001678"],"confidence":"Medium","gaps":["Mechanism connecting INPP4B to EZH2 unknown","Correlative human data"]},{"year":2023,"claim":"Defined a cell-intrinsic requirement for Inpp4b in B-1 cell maintenance and antibody responses, broadening its role in immune cell homeostasis.","evidence":"Conventional Inpp4b knockout mice, adoptive transfer, flow cytometry, and CD40-mediated B cell proliferation assays","pmids":["37389566"],"confidence":"Medium","gaps":["Signaling pathway underlying B-1 defect not defined","Whether phosphatase activity is required untested"]},{"year":2024,"claim":"Established INPP4B as a hallmark of tissue-resident ILC1s and intratumoral NK cells, required for their AKT-dependent survival and antitumor immunity.","evidence":"scRNA-seq, conditional Inpp4b knockout, apoptosis and AKT-phosphorylation assays, and intratumoral immune-cell and tumor-growth quantification","pmids":["38197946"],"confidence":"High","gaps":["How a PI3K/AKT-suppressing phosphatase promotes AKT-dependent survival mechanistically unresolved","Lipid substrate in this cell type not measured"]},{"year":2025,"claim":"Connected INPP4B to lysosomal exocytosis, showing it drives TRPML1-dependent FN1 secretion to promote PDAC migration and invasion.","evidence":"Overexpression/knockdown in PDAC cells, FN1 secretion assays, TRPML1 inhibition/knockdown, F-actin/FAK readouts, and invasion assays","pmids":["40962057"],"confidence":"Medium","gaps":["Phosphoinositide intermediate linking INPP4B to TRPML1 not identified","Single-lab study"]},{"year":null,"claim":"It remains unresolved how a single phosphatase produces opposing tumor-suppressive (AKT-suppressing) and oncogenic (SGK3/Wnt-activating) outputs, and what molecular determinants direct its localization and substrate choice across cell types.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model linking localization to substrate selection","Physiological protein phosphatase substrates unidentified","Mechanism reconciling AKT suppression with AKT-dependent immune-cell survival unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[1,2,5,11,19]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[2]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[0]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[4,11,12]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[11,19,23]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[13]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,3,5,11]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[12,13,23]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[9,18]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[20,24]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[19]}],"complexes":["BRCA1/ATM/ATR complex"],"partners":["RAB7","ATR","BRCA1","SYNJ1","PIK3C2A"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O15327","full_name":"Inositol polyphosphate 4-phosphatase type II","aliases":["Type II inositol 3,4-bisphosphate 4-phosphatase"],"length_aa":924,"mass_kda":104.7,"function":"Catalyzes the hydrolysis of the 4-position phosphate of phosphatidylinositol 3,4-bisphosphate, inositol 1,3,4-trisphosphate and inositol 3,4-trisphosphate (PubMed:24070612, PubMed:24591580). Plays a role in the late stages of macropinocytosis by dephosphorylating phosphatidylinositol 3,4-bisphosphate in membrane ruffles (PubMed:24591580). The lipid phosphatase activity is critical for tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival (PubMed:19647222, PubMed:24070612)","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/O15327/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/INPP4B","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/INPP4B","total_profiled":1310},"omim":[{"mim_id":"607494","title":"INOSITOL POLYPHOSPHATE-4-PHOSPHATASE, TYPE II, 105-KD; INPP4B","url":"https://www.omim.org/entry/607494"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Centrosome","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/INPP4B"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"O15327","domains":[{"cath_id":"2.60.40.150","chopping":"31-128_139-186","consensus_level":"medium","plddt":83.5342,"start":31,"end":186},{"cath_id":"-","chopping":"342-374_629-913","consensus_level":"high","plddt":95.2848,"start":342,"end":913},{"cath_id":"1.20.120,1.20.120","chopping":"399-481_524-541_577-601","consensus_level":"medium","plddt":88.324,"start":399,"end":601}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O15327","model_url":"https://alphafold.ebi.ac.uk/files/AF-O15327-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O15327-F1-predicted_aligned_error_v6.png","plddt_mean":82.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=INPP4B","jax_strain_url":"https://www.jax.org/strain/search?query=INPP4B"},"sequence":{"accession":"O15327","fasta_url":"https://rest.uniprot.org/uniprotkb/O15327.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O15327/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O15327"}},"corpus_meta":[{"pmid":"25458846","id":"PMC_25458846","title":"SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer.","date":"2014","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/25458846","citation_count":128,"is_preprint":false},{"pmid":"21224358","id":"PMC_21224358","title":"Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21224358","citation_count":121,"is_preprint":false},{"pmid":"21487159","id":"PMC_21487159","title":"INPP4B: the new kid on the PI3K block.","date":"2011","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/21487159","citation_count":95,"is_preprint":false},{"pmid":"25883022","id":"PMC_25883022","title":"In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes.","date":"2015","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/25883022","citation_count":85,"is_preprint":false},{"pmid":"25883023","id":"PMC_25883023","title":"INPP4B Is a PtdIns(3,4,5)P3 Phosphatase That Can Act as a Tumor Suppressor.","date":"2015","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/25883023","citation_count":67,"is_preprint":false},{"pmid":"25277204","id":"PMC_25277204","title":"Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25277204","citation_count":66,"is_preprint":false},{"pmid":"31968218","id":"PMC_31968218","title":"Exosomes derived from human bone marrow mesenchymal stem cells transfer miR-222-3p to suppress acute myeloid leukemia cell proliferation by targeting IRF2/INPP4B.","date":"2020","source":"Molecular and cellular probes","url":"https://pubmed.ncbi.nlm.nih.gov/31968218","citation_count":64,"is_preprint":false},{"pmid":"26411369","id":"PMC_26411369","title":"INPP4B is an oncogenic regulator in human colon cancer.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26411369","citation_count":57,"is_preprint":false},{"pmid":"27062697","id":"PMC_27062697","title":"Mir-765 promotes cell proliferation by downregulating INPP4B expression in human hepatocellular carcinoma.","date":"2016","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/27062697","citation_count":55,"is_preprint":false},{"pmid":"34035258","id":"PMC_34035258","title":"INPP4B promotes PI3Kα-dependent late endosome formation and Wnt/β-catenin signaling in breast cancer.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34035258","citation_count":53,"is_preprint":false},{"pmid":"28224609","id":"PMC_28224609","title":"miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer.","date":"2017","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28224609","citation_count":50,"is_preprint":false},{"pmid":"25736313","id":"PMC_25736313","title":"Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25736313","citation_count":48,"is_preprint":false},{"pmid":"25736236","id":"PMC_25736236","title":"INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia.","date":"2015","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/25736236","citation_count":47,"is_preprint":false},{"pmid":"24051093","id":"PMC_24051093","title":"INPP4B-mediated tumor resistance is associated with modulation of glucose metabolism via hexokinase 2 regulation in laryngeal cancer cells.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24051093","citation_count":47,"is_preprint":false},{"pmid":"32513774","id":"PMC_32513774","title":"The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer.","date":"2020","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/32513774","citation_count":45,"is_preprint":false},{"pmid":"16631325","id":"PMC_16631325","title":"Characterization of the murine Inpp4b gene and identification of a novel isoform.","date":"2006","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/16631325","citation_count":42,"is_preprint":false},{"pmid":"29516642","id":"PMC_29516642","title":"INPP4B restrains cell proliferation and metastasis via regulation of the PI3K/AKT/SGK pathway.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29516642","citation_count":41,"is_preprint":false},{"pmid":"26573229","id":"PMC_26573229","title":"INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26573229","citation_count":41,"is_preprint":false},{"pmid":"24288008","id":"PMC_24288008","title":"A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms.","date":"2013","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/24288008","citation_count":40,"is_preprint":false},{"pmid":"23551093","id":"PMC_23551093","title":"Phosphoinositide 3-kinase and INPP4B in human breast cancer.","date":"2013","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23551093","citation_count":39,"is_preprint":false},{"pmid":"25248616","id":"PMC_25248616","title":"INPP4B suppresses prostate cancer cell invasion.","date":"2014","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/25248616","citation_count":37,"is_preprint":false},{"pmid":"28915933","id":"PMC_28915933","title":"miR-1290 Contributes to Colorectal Cancer Cell Proliferation by Targeting INPP4B.","date":"2017","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/28915933","citation_count":34,"is_preprint":false},{"pmid":"24500884","id":"PMC_24500884","title":"Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.","date":"2014","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24500884","citation_count":31,"is_preprint":false},{"pmid":"25126743","id":"PMC_25126743","title":"Epigenetic inactivation of inositol polyphosphate 4-phosphatase B (INPP4B), a regulator of PI3K/AKT signaling pathway in EBV-associated nasopharyngeal carcinoma.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25126743","citation_count":29,"is_preprint":false},{"pmid":"27179609","id":"PMC_27179609","title":"miR-937 contributes to the lung cancer cell proliferation by targeting INPP4B.","date":"2016","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27179609","citation_count":28,"is_preprint":false},{"pmid":"28196852","id":"PMC_28196852","title":"INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC.","date":"2017","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/28196852","citation_count":27,"is_preprint":false},{"pmid":"28656250","id":"PMC_28656250","title":"MicroRNA-605 functions as a tumor suppressor by targeting INPP4B in melanoma.","date":"2017","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/28656250","citation_count":27,"is_preprint":false},{"pmid":"25542038","id":"PMC_25542038","title":"An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25542038","citation_count":25,"is_preprint":false},{"pmid":"25868852","id":"PMC_25868852","title":"Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25868852","citation_count":25,"is_preprint":false},{"pmid":"31913757","id":"PMC_31913757","title":"TGFβ receptor endocytosis and Smad signaling require synaptojanin1, PI3K-C2α-, and INPP4B-mediated phosphoinositide conversions.","date":"2020","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/31913757","citation_count":24,"is_preprint":false},{"pmid":"30876449","id":"PMC_30876449","title":"IRF2-INPP4B-mediated autophagy suppresses apoptosis in acute myeloid leukemia cells.","date":"2019","source":"Biological research","url":"https://pubmed.ncbi.nlm.nih.gov/30876449","citation_count":24,"is_preprint":false},{"pmid":"25284366","id":"PMC_25284366","title":"INPP4B is highly expressed in prostate intermediate cells and its loss of expression in prostate carcinoma predicts for recurrence and poor long term survival.","date":"2014","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/25284366","citation_count":24,"is_preprint":false},{"pmid":"27318090","id":"PMC_27318090","title":"INPP4B reverses docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27318090","citation_count":22,"is_preprint":false},{"pmid":"23078915","id":"PMC_23078915","title":"Role of the inositol polyphosphate-4-phosphatase type II Inpp4b in the generation of ovarian teratomas.","date":"2012","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/23078915","citation_count":21,"is_preprint":false},{"pmid":"29343273","id":"PMC_29343273","title":"INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia.","date":"2018","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/29343273","citation_count":20,"is_preprint":false},{"pmid":"33772116","id":"PMC_33772116","title":"INPP4B protects from metabolic syndrome and associated disorders.","date":"2021","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/33772116","citation_count":19,"is_preprint":false},{"pmid":"28261855","id":"PMC_28261855","title":"INPP4B overexpression suppresses migration, invasion and angiogenesis of human prostate cancer cells.","date":"2017","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28261855","citation_count":18,"is_preprint":false},{"pmid":"24070612","id":"PMC_24070612","title":"Determinants of the tumor suppressor INPP4B protein and lipid phosphatase activities.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24070612","citation_count":18,"is_preprint":false},{"pmid":"36147923","id":"PMC_36147923","title":"INPP4B inhibits glioma cell proliferation and immune escape via inhibition of the PI3K/AKT signaling pathway.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36147923","citation_count":17,"is_preprint":false},{"pmid":"31123408","id":"PMC_31123408","title":"INPP4B inhibits cell proliferation, invasion and chemoresistance in human hepatocellular carcinoma.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31123408","citation_count":16,"is_preprint":false},{"pmid":"31179504","id":"PMC_31179504","title":"INPP4B exerts a dual function in the stemness of colorectal cancer stem-like cells through regulating Sox2 and Nanog expression.","date":"2020","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/31179504","citation_count":16,"is_preprint":false},{"pmid":"34216856","id":"PMC_34216856","title":"The INPP4B paradox: Like PTEN, but different.","date":"2021","source":"Advances in biological regulation","url":"https://pubmed.ncbi.nlm.nih.gov/34216856","citation_count":15,"is_preprint":false},{"pmid":"28579269","id":"PMC_28579269","title":"IRF2-INPP4B axis participates in the development of acute myeloid leukemia by regulating cell growth and survival.","date":"2017","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/28579269","citation_count":15,"is_preprint":false},{"pmid":"27402148","id":"PMC_27402148","title":"Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor.","date":"2016","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/27402148","citation_count":14,"is_preprint":false},{"pmid":"33020300","id":"PMC_33020300","title":"Estrogen receptor β regulates AKT activity through up-regulation of INPP4B and inhibits migration of prostate cancer cell line PC-3.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33020300","citation_count":13,"is_preprint":false},{"pmid":"24420152","id":"PMC_24420152","title":"INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24420152","citation_count":13,"is_preprint":false},{"pmid":"27342972","id":"PMC_27342972","title":"INPP4B-mediated DNA repair pathway confers resistance to chemotherapy in acute myeloid leukemia.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27342972","citation_count":12,"is_preprint":false},{"pmid":"35640821","id":"PMC_35640821","title":"ELOVL2 restrains cell proliferation, migration, and invasion of prostate cancer via regulation of the tumor suppressor INPP4B.","date":"2022","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/35640821","citation_count":12,"is_preprint":false},{"pmid":"29415082","id":"PMC_29415082","title":"SubID, a non-median dichotomization tool for heterogeneous populations, reveals the pan-cancer significance of INPP4B and its regulation by EVI1 in AML.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29415082","citation_count":11,"is_preprint":false},{"pmid":"25528023","id":"PMC_25528023","title":"INPP4B and RAD50 have an interactive effect on survival after breast cancer.","date":"2014","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/25528023","citation_count":10,"is_preprint":false},{"pmid":"35760104","id":"PMC_35760104","title":"Inhibition of lipid kinase PIKfyve reveals a role for phosphatase Inpp4b in the regulation of PI(3)P-mediated lysosome dynamics through VPS34 activity.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35760104","citation_count":10,"is_preprint":false},{"pmid":"31114251","id":"PMC_31114251","title":"INPP4B promotes colorectal cancer cell proliferation by activating mTORC1 signaling and cap-dependent translation.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31114251","citation_count":9,"is_preprint":false},{"pmid":"32115737","id":"PMC_32115737","title":"IRF2-INPP4B axis inhibits apoptosis of acute myeloid leukaemia cells via regulating T helper 1/2 cell differentiation.","date":"2020","source":"Cell biochemistry and function","url":"https://pubmed.ncbi.nlm.nih.gov/32115737","citation_count":9,"is_preprint":false},{"pmid":"24837011","id":"PMC_24837011","title":"Effects of INPP4B gene transfection combined with PARP inhibitor on castration therapy-resistant prostate cancer cell line, PC3.","date":"2014","source":"Urologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24837011","citation_count":8,"is_preprint":false},{"pmid":"29644781","id":"PMC_29644781","title":"INPP4B overexpression and c-KIT downregulation in human achalasia.","date":"2018","source":"Neurogastroenterology and motility","url":"https://pubmed.ncbi.nlm.nih.gov/29644781","citation_count":8,"is_preprint":false},{"pmid":"30411790","id":"PMC_30411790","title":"Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial.","date":"2018","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30411790","citation_count":8,"is_preprint":false},{"pmid":"33879096","id":"PMC_33879096","title":"Expression and functional characterization of INPP4B in gallbladder cancer patients and gallbladder cancer cells.","date":"2021","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33879096","citation_count":7,"is_preprint":false},{"pmid":"38197946","id":"PMC_38197946","title":"Inositol phosphatase INPP4B sustains ILC1s and intratumoral NK cells through an AKT-driven pathway.","date":"2024","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38197946","citation_count":7,"is_preprint":false},{"pmid":"36612130","id":"PMC_36612130","title":"The FDA-Approved Drug Pyrvinium Selectively Targets ER+ Breast Cancer Cells with High INPP4B Expression.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36612130","citation_count":7,"is_preprint":false},{"pmid":"33520362","id":"PMC_33520362","title":"Ese-3 contributes to colon cancer progression by downregulating EHD2 and transactivating INPP4B.","date":"2021","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33520362","citation_count":7,"is_preprint":false},{"pmid":"26577950","id":"PMC_26577950","title":"Biological and clinical significance of loss of heterozygosity at the INPP4B gene locus in Japanese breast cancer.","date":"2015","source":"Breast (Edinburgh, Scotland)","url":"https://pubmed.ncbi.nlm.nih.gov/26577950","citation_count":6,"is_preprint":false},{"pmid":"33500628","id":"PMC_33500628","title":"lncRNA RAET1K Promotes the Progression of Acute Myeloid Leukemia by Targeting miR-503-5p/INPP4B Axis.","date":"2021","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33500628","citation_count":6,"is_preprint":false},{"pmid":"28189677","id":"PMC_28189677","title":"Functional identification of a novel transcript variant of INPP4B in human colon and breast cancer cells.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28189677","citation_count":5,"is_preprint":false},{"pmid":"39960210","id":"PMC_39960210","title":"The IRF2-INPP4B Pathway Aggravates Acute Myeloid Leukemia.","date":"2025","source":"Turkish journal of haematology : official journal of Turkish Society of Haematology","url":"https://pubmed.ncbi.nlm.nih.gov/39960210","citation_count":4,"is_preprint":false},{"pmid":"38329467","id":"PMC_38329467","title":"INPP4B ensures that ILC1s and NK cells set up a productive home office.","date":"2024","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38329467","citation_count":4,"is_preprint":false},{"pmid":"35540690","id":"PMC_35540690","title":"Retracted Article: LncRNA ZEB2-AS1 regulates the drug resistance of acute myeloid leukemia via the miR-142-3p/INPP4B axis.","date":"2019","source":"RSC advances","url":"https://pubmed.ncbi.nlm.nih.gov/35540690","citation_count":4,"is_preprint":false},{"pmid":"38318760","id":"PMC_38318760","title":"Role of INPP4B in the proliferation, migration, invasion, and survival of human endometrial cancer cells.","date":"2024","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/38318760","citation_count":3,"is_preprint":false},{"pmid":"40754682","id":"PMC_40754682","title":"Multi-omics integration analysis identifies INPP4B as a T-cell-specific activation suppressor.","date":"2025","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40754682","citation_count":3,"is_preprint":false},{"pmid":"38852646","id":"PMC_38852646","title":"INPP4B suppresses HER2-induced mesenchymal transition in HER2+ breast cancer and enhances sensitivity to Lapatinib.","date":"2024","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38852646","citation_count":2,"is_preprint":false},{"pmid":"37389566","id":"PMC_37389566","title":"Regulation of B-1 cell numbers and B cell-mediated antibody production by Inpp4b.","date":"2023","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37389566","citation_count":2,"is_preprint":false},{"pmid":"38001678","id":"PMC_38001678","title":"Regulation of EZH2 Expression by INPP4B in Normal Prostate and Primary Prostate Cancer.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/38001678","citation_count":2,"is_preprint":false},{"pmid":"36993823","id":"PMC_36993823","title":"Tumor Suppressor Role of INPP4B in Chemoresistant Retinoblastoma.","date":"2023","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36993823","citation_count":2,"is_preprint":false},{"pmid":"38246071","id":"PMC_38246071","title":"Investigating the multifaceted cooperation of autophagy, PI3K/AKT signaling pathways, and INPP4B gene in de novo acute myeloid leukemia patients.","date":"2023","source":"Current research in translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38246071","citation_count":2,"is_preprint":false},{"pmid":"31695845","id":"PMC_31695845","title":"Investigating the duality of Inpp4b function in the cellular transformation of mouse fibroblasts.","date":"2019","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/31695845","citation_count":2,"is_preprint":false},{"pmid":"41219999","id":"PMC_41219999","title":"Upregulation of miR-151a-5p in high DFI sperm induces DNA damage and mitochondrial dysfunction by targeting INPP4B and VAMP1.","date":"2025","source":"Reproductive biology and endocrinology : RB&E","url":"https://pubmed.ncbi.nlm.nih.gov/41219999","citation_count":1,"is_preprint":false},{"pmid":"40962057","id":"PMC_40962057","title":"The lipid phosphatase INPP4B controls pancreatic cancer cell migration and invasion by regulating fibronectin exocytosis.","date":"2025","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40962057","citation_count":0,"is_preprint":false},{"pmid":"39507966","id":"PMC_39507966","title":"[Preliminary Study of the Role of INPP4B in Promoting Colorectal Cancer Metastasis and the Mechanisms Involved].","date":"2024","source":"Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition","url":"https://pubmed.ncbi.nlm.nih.gov/39507966","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.08.18.25333929","title":"Artificial Intelligence-Guided Molecular Determinants of PI3K Pathway Alterations in Early-Onset Colorectal Cancer Among High-Risk Groups Receiving FOLFOX","date":"2025-08-21","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.18.25333929","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.02.18.638894","title":"A Genetic Analysis of Lipid Metabolism Regulation in Han Chinese Youth in Xinjiang via Extreme Phenotypic Strategies","date":"2025-02-23","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.18.638894","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.02.27.25323065","title":"Comparative genomic analysis of key oncogenic pathways in hepatocellular carcinoma among diverse populations","date":"2025-03-03","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.27.25323065","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.26.609679","title":"Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion","date":"2024-08-26","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.26.609679","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.23.624931","title":"Mapping enhancer-gene regulatory interactions from single-cell data","date":"2024-11-24","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.23.624931","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44605,"output_tokens":7483,"usd":0.12303,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16740,"output_tokens":7327,"usd":0.133437,"stage2_stop_reason":"end_turn"},"total_usd":0.256467,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"INPP4B protein contains a consensus phosphatase catalytic site and a C2 domain; the C2 domain interacts preferentially with phosphatidic acid and PI(3,4,5)P3 lipids. Two isoforms exist: Inpp4bα is mainly cytosolic, while Inpp4bβ localizes to the Golgi apparatus, suggesting distinct cellular functions for each isoform.\",\n      \"method\": \"cDNA isolation, domain characterization, lipid-binding assay (C2 domain binding to lipid panels), subcellular localization by fractionation/imaging\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct lipid-binding assay and subcellular fractionation/localization in a single focused study with multiple methods\",\n      \"pmids\": [\"16631325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"INPP4B dephosphorylates phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2), leading to reduced Akt phosphorylation and activity. In prostate cancer cells, androgen receptor (AR) induces INPP4B expression (but not PTEN), and this induction requires the transcriptional coactivator NCoR. INPP4B depletion activated Akt and increased cellular proliferation.\",\n      \"method\": \"siRNA knockdown, Western blot for p-Akt, reporter/expression assays for AR-mediated induction, NCoR co-activator studies\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined signaling readout and transcriptional mechanism, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"21224358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"INPP4B has protein tyrosine phosphatase (PTP) activity in addition to lipid phosphatase activity, demonstrated by dephosphorylation of synthetic phosphotyrosine analogs (pNPP and DiFMUP). Mutagenesis of the catalytic site (CX5R motif, C842KSAKDR): K843M increased pNPP hydrolysis; K846M abolished lipid phosphatase activity without affecting PTP activity; D847E ablated PTP activity and significantly reduced lipid phosphatase activity. INPP4B, but not PTEN, reduced tyrosine phosphorylation of Akt1, with both lipid and protein phosphatase activities contributing.\",\n      \"method\": \"In vitro phosphatase assays (pNPP, DiFMUP), site-directed mutagenesis of catalytic residues, Western blot for Akt1 tyrosine phosphorylation\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic assay combined with systematic active-site mutagenesis identifying distinct residues for lipid vs. protein phosphatase activities\",\n      \"pmids\": [\"24070612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SGK3 is activated downstream of PIK3CA in a manner dependent on INPP4B. INPP4B expression enhances SGK3 activation while suppressing Akt phosphorylation. SGK3 activation downstream of PIK3CA/INPP4B is required for 3D proliferation, invasive migration, and tumorigenesis in vivo. SGK3 targets the metastasis suppressor NDRG1 for degradation by Fbw7.\",\n      \"method\": \"Overexpression and knockdown studies, in vitro 3D proliferation and invasion assays, in vivo tumorigenesis, Western blot for p-SGK3 and p-Akt\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal gain/loss-of-function, multiple orthogonal functional assays (3D proliferation, invasion, in vivo), mechanistic pathway placement; replicated in multiple subsequent studies\",\n      \"pmids\": [\"25458846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"INPP4B is enriched at early endosomes in thyroid cancer cells, where it selectively inhibits AKT2 (but not AKT1) activation, suppressing tumor proliferation and anchorage-independent growth. INPP4B and PTEN do not act epistatically in thyroid oncogenesis; combined heterozygous Pten loss and Inpp4b deletion in mice produces lethal metastatic follicular thyroid cancer, while single knockouts do not.\",\n      \"method\": \"Subcellular fractionation/immunofluorescence (endosome localization), genetic mouse models (Pten+/- × Inpp4b-/-), isoform-specific Akt activation assays, 3D growth assays\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic epistasis in mouse models combined with subcellular localization and isoform-specific AKT activation assays in a single rigorous study\",\n      \"pmids\": [\"25883022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"INPP4B directly dephosphorylates PtdIns(3,4,5)P3 (PIP3) in vitro, acting as a PIP3 3-phosphatase. In vivo, combined Inpp4b deletion and Pten heterozygosity synergistically increases PtdIns(3,4,5)P3 levels and activates downstream AKT signaling in thyroid cells, inducing malignant thyroid cancer with lung metastases.\",\n      \"method\": \"In vitro phosphatase assay (direct PIP3 dephosphorylation), mouse genetic models (Inpp4bΔ/Δ and Pten+/-), phosphoinositide mass measurement\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro biochemical assay demonstrating PIP3 phosphatase activity combined with in vivo genetic model; independent replication of thyroid cancer phenotype across two concurrent papers\",\n      \"pmids\": [\"25883023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Loss of INPP4B causes a DNA repair defect associated with reduced BRCA1, ATM, and ATR protein stability. INPP4B forms a protein complex with ATR and BRCA1 (demonstrated by GST pulldown and 293T overexpression assays). INPP4B-deficient cells show increased sensitivity to PARP inhibitors comparable to BRCA1 loss, both in vitro and in vivo xenograft models.\",\n      \"method\": \"GST pulldown, co-overexpression assays in 293T cells, comet assay, γH2AX/RAD51/53BP1 foci quantification, PARP inhibitor sensitivity assays in 2D/3D culture and xenografts\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — protein-protein interaction by GST pulldown and overexpression Co-IP, combined with functional DNA repair assays, single lab\",\n      \"pmids\": [\"25868852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In AML, INPP4B overexpression confers leukemic resistance to chemotherapy (cytosine arabinoside, daunorubicin, etoposide) through a phosphatase-dependent but Akt-independent mechanism; expression of the phosphatase-dead INPP4B C842A variant failed to confer resistance in vitro or in vivo.\",\n      \"method\": \"Ectopic overexpression of wild-type vs. phosphatase-dead (C842A) INPP4B, in vitro drug resistance assays, in vivo xenograft chemotherapy resistance, siRNA knockdown\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — catalytic mutant comparison in vitro and in vivo establishes phosphatase-dependent resistance mechanism, single lab\",\n      \"pmids\": [\"25736313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In colon cancer cells, INPP4B upregulation is driven by Ets-1-mediated transcriptional activation. INPP4B promotes Akt and SGK3 activation in colon cancer and this is associated with inactivation of PTEN through its protein phosphatase activity. INPP4B silencing blocks Akt and SGK3 activation and inhibits colon cancer cell proliferation and xenograft growth.\",\n      \"method\": \"Ets-1 promoter activity assays, siRNA knockdown, overexpression studies, Western blot for p-Akt/p-SGK3, xenograft growth assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptional mechanism identified with functional follow-up, single lab with multiple methods\",\n      \"pmids\": [\"26411369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"INPP4B-mediated resistance to irradiation in laryngeal cancer cells is associated with increased aerobic glycolysis. INPP4B overexpression enhances aerobic glycolysis through upregulation of hexokinase 2 (HK2), mediated via the Akt-mTOR pathway. Co-depletion of INPP4B and HK2 sensitizes radioresistant cells to irradiation and anticancer drugs.\",\n      \"method\": \"INPP4B overexpression/knockdown, glycolysis measurement, HK2 expression analysis, Akt-mTOR pathway inhibitor experiments, co-depletion assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway epistasis via pharmacological inhibition and co-depletion studies, single lab\",\n      \"pmids\": [\"24051093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"INPP4B suppresses prostate cancer cell invasion in vitro and in vivo. Mechanistically, INPP4B suppresses oncogenic PKC signaling independently of the PI3K/Akt pathway, as PI3K/Akt inhibition did not reproduce INPP4B-mediated suppression of IL-8 but PKC inhibition did. INPP4B reduces phosphorylation of PKC, expression of BIRC5, and downstream target COX-2.\",\n      \"method\": \"De novo INPP4B expression in invasive PC-3 cells, in vitro invasion assays, in vivo invasion assay, global gene expression analysis, PI3K/Akt and PKC pathway inhibitor comparisons\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological epistasis distinguishing PKC from PI3K/Akt as INPP4B effector pathway, single lab with multiple methods\",\n      \"pmids\": [\"25248616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"INPP4B localizes to late endosomes via interaction with Rab7 in PIK3CA-mutant ER+ breast cancer cells. This endosomal localization drives PI3Kα-dependent conversion of PI(3,4)P2 to PI(3)P on late endosomes, increasing late endosome/lysosome number and cargo trafficking, resulting in GSK3β lysosomal degradation and activation of Wnt/β-catenin signaling. INPP4B-mediated proliferation requires the PI(3)P-effector Hrs, and Wnt inhibition blocks INPP4B-driven tumor growth.\",\n      \"method\": \"Integrated proteomics/transcriptomics/imaging, Rab7 interaction assay, phosphoinositide measurement, lysosome number quantification, GSK3β degradation assay, Wnt pathway reporter assays, Hrs depletion rescue experiments, in vivo tumor growth\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (proteomics, imaging, phosphoinositide quantification, in vivo), Rab7 interaction established, downstream mechanism validated with genetic rescue in a single rigorous study\",\n      \"pmids\": [\"34035258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"INPP4B deficiency increases PI(3,4)P2 levels specifically in endocytic vesicles (not at the plasma membrane), delays EGFR and MET lysosomal degradation while promoting their recycling, thus enhancing RTK signaling duration and amplitude upon growth factor stimulation. Loss of INPP4B in TNBC increases both AKT and MEK/ERK pathway activation.\",\n      \"method\": \"INPP4B knockout mouse model (genetically engineered TNBC), phosphoinositide localization assays, EGFR/MET trafficking assays (pulse-chase, receptor recycling/degradation), PI3K and MEK inhibitor sensitivity in vivo\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetically engineered mouse model plus mechanistic RTK trafficking experiments with phosphoinositide localization, multiple orthogonal methods\",\n      \"pmids\": [\"32513774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"INPP4B is required for TGFβ receptor endocytosis. Specifically, INPP4B (the 4'-phosphatase), together with synaptojanin1 and PI3K-C2α, mediates sequential phosphoinositide conversions essential for TGFβ-induced endocytosis of TGFβ receptor, Smad2 and Smad3 activation. INPP4B knockdown abolished these signaling events.\",\n      \"method\": \"siRNA-mediated knockdown of INPP4B and pathway components, live-cell phosphoinositide imaging at the plasma membrane, TGFβ receptor endocytosis assays, Smad2/3 phosphorylation assays\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — specific knockdown with defined molecular readouts (phosphoinositide dynamics, receptor endocytosis, Smad signaling), single lab\",\n      \"pmids\": [\"31913757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In PTEN-null TNBC cells, INPP4B loss decreases basal p-Akt and proliferation. Accumulated PI(3,4)P2 (when both PTEN and INPP4B are lost) acts as an inhibitory second messenger toward PI3K, revealing a negative feedback mechanism. INPP4B overexpression desensitizes cells to PI3K inhibitors in a phosphatase activity-dependent manner.\",\n      \"method\": \"siRNA knockdown and overexpression of INPP4B in PTEN-null TNBC lines, phospho-Akt Western blot, PI3K isoform-selective inhibitor sensitivity assays\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphatase-activity dependence established, multiple TNBC cell lines, single lab\",\n      \"pmids\": [\"28196852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In NPM1-mutated AML cells, INPP4B promotes cell survival through SGK3 activation without affecting Akt. INPP4B overexpression increases PI(3,4)P2 to PI(3)P conversion (measured by ELISA), and SGK3 knockdown abrogates INPP4B-induced proliferation. High INPP4B levels in NPM1-mutated AML are caused at least partly by the NPM1 mutant acting through ERK/Ets-1 signaling.\",\n      \"method\": \"INPP4B overexpression/knockdown, SGK3 knockdown rescue assay, PI(3,4)P2 and PI(3)P ELISA, ERK/Ets-1 pathway analysis, colony formation and proliferation assays\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphoinositide mass measurement plus SGK3 rescue epistasis in a single lab, multiple orthogonal methods\",\n      \"pmids\": [\"29343273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In AML, INPP4B-mediated chemoresistance involves enhanced ATM-dependent DNA repair. INPP4B knockdown reduces ATM expression and downstream p-ATM, p-BRCA1, p-ATR, and p-RAD51 activation, as well as nuclear p65 localization. Re-activation of p65 rescues ATM pathway activity after INPP4B knockdown, placing NF-κB (p65) between INPP4B and ATM in the DNA repair pathway.\",\n      \"method\": \"INPP4B knockdown, γH2AX assay, Western blot for ATM/p-ATM/p-BRCA1/p-ATR/p-RAD51, NF-κB p65 nuclear localization assay, p65 rescue experiments, cytarabine sensitivity assays\",\n      \"journal\": \"Tumour biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway epistasis via p65 rescue experiments, multiple DNA repair markers, single lab\",\n      \"pmids\": [\"27342972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IRF2 binds the INPP4B promoter and transcriptionally activates INPP4B expression in AML cells, placing IRF2 upstream of INPP4B in a signaling axis regulating AML cell growth and apoptosis. Restoration of INPP4B expression rescues the effects of IRF2 knockdown on apoptosis and colony formation.\",\n      \"method\": \"IRF2 promoter binding (ChIP-like assay implied), INPP4B rescue after IRF2 knockdown, colony formation and apoptosis assays in AML cell lines\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptional regulatory relationship established with functional rescue, single lab\",\n      \"pmids\": [\"28579269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"INPP4B suppresses AKT and PKC signaling in the liver to improve insulin sensitivity. Loss of INPP4B leads to proteolytic cleavage and activation of SREBP1, a key regulator of de novo lipogenesis, driving upregulation of PPARG and lipogenic pathways. Inpp4b-/- mice on a high fat diet develop obesity, NAFLD, type II diabetes, and prostatic intraepithelial neoplasia driven by inflammation.\",\n      \"method\": \"Inpp4b knockout mice, high fat diet model, AKT/PKC phosphorylation assays, SREBP1 cleavage analysis by Western blot, metabolic phenotyping (energy expenditure, respiratory exchange ratio), histology\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knockout model with multiple orthogonal mechanistic readouts (SREBP1 cleavage, AKT/PKC signaling, metabolic parameters), single lab rigorous study\",\n      \"pmids\": [\"33772116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"INPP4B (Inpp4b) is required for normal lysosomal homeostasis and dynamics. In Inpp4b-deficient mouse embryonic fibroblasts, inhibition of PIKfyve causes massively enlarged lysosomes, disrupted lysosome fusion-fission dynamics, and impaired autophagy. Mechanistically, Inpp4b deficiency causes hyperactivation of VPS34 (PI3K class III), elevating lysosomal PtdIns(3)P levels, which is exacerbated when PIKfyve is inhibited.\",\n      \"method\": \"Inpp4b-deficient MEFs, PIKfyve inhibitor treatment, confocal fluorescence imaging of lysosomes, HPLC scintillation quantification of 3H-myo-inositol labeled PtdIns, PtdIns immunofluorescence, VPS34 activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct phosphoinositide quantification plus enzymatic activity assay in genetic model, multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"35760104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"INPP4B is a hallmark feature of tissue-resident ILC1s and intratumoral NK cells. Conditional deletion of Inpp4b in ILC1s and NK cells reduces tissue-resident ILC1 homeostasis (but not circulating NK cells) at steady state through increased apoptosis and reduced AKT activation. INPP4B expression is necessary for ILC1/NK cell presence in the intratumoral environment and for antitumor immunity.\",\n      \"method\": \"scRNA-seq atlas, conditional Inpp4b knockout mice, flow cytometry (apoptosis, cell numbers), AKT phosphorylation assays, intratumoral NK/ILC1 quantification, tumor growth assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional knockout in specific cell types with multiple orthogonal functional readouts (apoptosis, AKT activation, tumor immunity), in vivo\",\n      \"pmids\": [\"38197946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Loss of INPP4B (but not PTEN) in prostate cells decreases EZH2 expression and reduces H3 methylation levels. INPP4B and EZH2 are positively correlated in normal prostate and early-stage tumors (unlike PTEN, which is inversely correlated with EZH2). INPP4B loss elevates p53 protein expression and Akt phosphorylation in murine prostates, but unlike PTEN loss does not affect SMAD4 protein or Pml mRNA.\",\n      \"method\": \"INPP4B knockdown in human prostate cancer cell lines, Inpp4b knockout mouse prostate analysis, Western blot for EZH2 and H3 methylation, single-cell transcriptomic analysis\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro knockdown plus in vivo mouse model demonstrating distinct downstream effectors vs. PTEN, single lab\",\n      \"pmids\": [\"38001678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Estrogen receptor β1 (ERβ1) induces INPP4B expression in prostate cancer cells in response to ERβ ligands, leading to inhibition of Akt activity and reduction in cell migration, providing a mechanism for androgen-independent regulation of INPP4B.\",\n      \"method\": \"ERβ1 expression engineering in PC3 cells, ERβ ligand treatment, Western blot for INPP4B and p-Akt, cell migration assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function with defined molecular and functional readouts, single lab\",\n      \"pmids\": [\"33020300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"INPP4B promotes fibronectin 1 (FN1) secretion via TRPML1 (transient receptor potential cation channel mucolipin subfamily member 1)-dependent lysosomal exocytosis in pancreatic ductal adenocarcinoma. INPP4B-mediated regulation of F-actin formation, focal adhesion kinase activation, and increased cell migration and invasion depend on FN1 exocytosis.\",\n      \"method\": \"INPP4B overexpression/knockdown in PDAC cells, FN1 secretion assay, TRPML1 inhibitor/knockdown, F-actin staining, FAK phosphorylation Western blot, migration and invasion assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays with pathway dissection (TRPML1-FN1 axis), single lab\",\n      \"pmids\": [\"40962057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Inpp4b is required for normal B-1 cell numbers and B cell-mediated antibody production. Inpp4b deficiency intrinsically reduces peritoneal B-1 cells (but not B-2 cells) and impairs thymus-independent and thymus-dependent antigen-induced antibody production. CD40-mediated B cell proliferation is impaired upon Inpp4b ablation.\",\n      \"method\": \"Inpp4b conventional knockout mice, adoptive transfer studies, flow cytometry phenotyping, in vitro B cell activation and proliferation assays (CD40-mediated)\",\n      \"journal\": \"Scandinavian journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with adoptive transfer epistasis and in vitro functional assays, single lab\",\n      \"pmids\": [\"37389566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Inpp4b deficiency cooperates with SV40 T-Large antigen to promote cellular transformation in mouse embryonic fibroblasts, associated with increased phosphorylated-Akt levels. INPP4B overexpression in SV40 T-Large MEFs dampens transformation and reduces p-Akt. Inpp4b deficiency or overexpression was insufficient to induce transformation alone or in combination with H-Ras or E1A.\",\n      \"method\": \"MEF transformation assay with Inpp4b knockout and overexpression, SV40 T-Large/H-Ras/E1A co-expression, p-Akt Western blot\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in MEF transformation model, multiple oncogene combinations tested, single lab\",\n      \"pmids\": [\"31695845\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"INPP4B is a dual-specificity phosphoinositide phosphatase that hydrolyzes both PI(3,4)P2 (to PI(3)P) and PtdIns(3,4,5)P3 (to PtdIns(3,4)P2) to negatively regulate PI3K/AKT signaling; it also possesses protein tyrosine phosphatase activity and its precise oncogenic vs. tumor-suppressive output is context-dependent, determined by subcellular localization (cytosol, early or late endosomes, Golgi), cell type, and co-occurring mutations—with endosomal INPP4B generating PI(3)P to activate SGK3 and Wnt/β-catenin signaling in certain cancers, while cytosolic INPP4B degrades PI(3,4)P2 to suppress AKT in others; additionally, INPP4B regulates RTK trafficking, TGFβ receptor endocytosis, lysosomal homeostasis via VPS34, DNA repair through a BRCA1/ATM/ATR complex, metabolic signaling via SREBP1 cleavage in the liver, and innate immune cell survival through AKT-dependent mechanisms in tissue-resident ILC1s.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"INPP4B is a dual-specificity phosphoinositide phosphatase whose principal biochemical activity is hydrolysis of PI(3,4)P2 to PI(3)P, with additional direct PtdIns(3,4,5)P3 3-phosphatase activity and an intrinsic protein tyrosine phosphatase activity—the lipid and protein phosphatase functions being separable through distinct catalytic-site residues (K846 for lipid, D847 for protein activity) [#2, #5]. Through these activities it negatively regulates PI3K/AKT signaling, and combined loss of Inpp4b and Pten synergistically elevates PtdIns(3,4,5)P3 and AKT activation to drive metastatic thyroid cancer, establishing INPP4B as a tumor suppressor that acts non-epistatically with PTEN [#4, #5]. Its functional output is governed by subcellular localization: at late endosomes, Rab7-dependent INPP4B converts PI(3,4)P2 to PI(3)P to drive lysosomal GSK3β degradation and Wnt/β-catenin signaling, and the same PI(3,4)P2-to-PI(3)P conversion activates SGK3 (downstream of PIK3CA) to promote proliferation, invasion, and tumorigenesis in a manner independent of AKT [#3, #11, #15]. INPP4B controls endosomal phosphoinositide pools that regulate receptor trafficking—restraining EGFR/MET recycling and signaling duration and enabling TGFβ receptor endocytosis and Smad2/3 activation—and maintains lysosomal homeostasis and autophagy by limiting VPS34-driven lysosomal PtdIns(3)P [#12, #13, #19]. Beyond cancer cell signaling, INPP4B suppresses hepatic AKT/PKC signaling and SREBP1 cleavage to maintain insulin sensitivity and restrain lipogenesis, and supports AKT-dependent survival of tissue-resident ILC1s and B-1 cells [#18, #20, #24]. Its expression is transcriptionally controlled in a context-specific manner by androgen receptor/NCoR, ERβ1, Ets-1, and IRF2 [#1, #8, #17, #22].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Established INPP4B's domain architecture and isoform-specific localization, framing it as a lipid-interacting phosphatase with potentially distinct cytosolic versus Golgi functions.\",\n      \"evidence\": \"cDNA isolation, C2-domain lipid-binding assays, and subcellular fractionation/imaging of two isoforms\",\n      \"pmids\": [\"16631325\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Catalytic substrate not directly demonstrated in this study\", \"Functional consequence of isoform localization untested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated that INPP4B dephosphorylates PI(3,4)P2 to suppress AKT and proliferation, and that androgen receptor/NCoR drives its expression, positioning it as a PI3K/AKT tumor suppressor.\",\n      \"evidence\": \"siRNA knockdown with p-Akt Western blot and AR/NCoR transcriptional induction assays in prostate cancer cells\",\n      \"pmids\": [\"21224358\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not address direct PIP3 hydrolysis\", \"In vivo tumor suppression not tested here\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Resolved that INPP4B carries separable lipid and protein tyrosine phosphatase activities through distinct active-site residues, expanding its enzymatic repertoire beyond a single lipid substrate.\",\n      \"evidence\": \"In vitro pNPP/DiFMUP assays with systematic CX5R-motif mutagenesis and Akt1 tyrosine-phosphorylation readout\",\n      \"pmids\": [\"24070612\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological protein substrates of the PTP activity not identified\", \"Relative cellular contribution of each activity unquantified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Linked INPP4B to metabolic reprogramming, showing it can promote aerobic glycolysis and radioresistance via Akt-mTOR-driven HK2, an early sign of context-dependent oncogenic output.\",\n      \"evidence\": \"Overexpression/knockdown, glycolysis and HK2 measurement, pathway inhibitor and co-depletion experiments in laryngeal cancer cells\",\n      \"pmids\": [\"24051093\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism reconciling AKT suppression vs Akt-mTOR-HK2 activation unclear\", \"Single cancer context\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified SGK3 as an AKT-independent effector of INPP4B, explaining how INPP4B can promote proliferation, invasion, and tumorigenesis while suppressing AKT.\",\n      \"evidence\": \"Reciprocal gain/loss-of-function, 3D proliferation/invasion assays, in vivo tumorigenesis, and p-SGK3/NDRG1 readouts\",\n      \"pmids\": [\"25458846\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Lipid product (PI(3)P) driving SGK3 not directly measured here\", \"Subcellular site of SGK3 activation not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed INPP4B can suppress invasion through PKC rather than PI3K/Akt, broadening its effector landscape beyond phosphoinositide-AKT signaling.\",\n      \"evidence\": \"De novo expression in PC-3 cells, invasion assays, gene expression profiling, and PKC vs PI3K/Akt inhibitor comparisons\",\n      \"pmids\": [\"25248616\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical link between INPP4B and PKC not established\", \"Whether effect depends on lipid or protein phosphatase activity untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Established INPP4B as a bona fide tumor suppressor with direct PIP3 3-phosphatase activity that acts non-epistatically with PTEN in vivo.\",\n      \"evidence\": \"Two concurrent studies: direct in vitro PIP3 dephosphorylation, endosomal localization, isoform-specific AKT2 inhibition, and Pten+/-×Inpp4b-/- mouse thyroid cancer models\",\n      \"pmids\": [\"25883022\", \"25883023\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative in vivo contribution of PI(3,4)P2 vs PIP3 hydrolysis unresolved\", \"Why AKT2 but not AKT1 is targeted mechanistically unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Implicated INPP4B in DNA repair by showing it stabilizes a BRCA1/ATM/ATR complex and confers PARP-inhibitor sensitivity when lost.\",\n      \"evidence\": \"GST pulldown and 293T co-overexpression, comet/γH2AX/RAD51/53BP1 foci, and PARP inhibitor sensitivity in xenografts\",\n      \"pmids\": [\"25868852\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interaction shown by overexpression Co-IP without reciprocal endogenous validation\", \"Mechanism by which a phosphatase stabilizes repair proteins unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Revealed an oncogenic, phosphatase-dependent but Akt-independent role for INPP4B in conferring AML chemoresistance, formalizing its context-dependent duality.\",\n      \"evidence\": \"Wild-type vs phosphatase-dead C842A overexpression in drug resistance assays in vitro and in xenografts\",\n      \"pmids\": [\"25736313\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream effector of the Akt-independent resistance not defined here\", \"Relevant phosphoinositide product not measured\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed Ets-1-driven INPP4B promotes Akt and SGK3 activation in colon cancer, reinforcing transcriptional control and the SGK3 oncogenic axis.\",\n      \"evidence\": \"Ets-1 promoter assays, knockdown/overexpression, p-Akt/p-SGK3 Westerns, and xenograft growth\",\n      \"pmids\": [\"26411369\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Claimed PTEN inactivation via protein phosphatase activity not biochemically demonstrated\", \"Direct substrate undefined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Connected INPP4B chemoresistance in AML to ATM-dependent DNA repair via an NF-κB(p65)-to-ATM relay, linking the resistance and DNA-repair phenotypes.\",\n      \"evidence\": \"Knockdown with DNA-repair marker Westerns, p65 nuclear localization, and p65 rescue experiments\",\n      \"pmids\": [\"27342972\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How INPP4B phosphatase activity regulates p65 not established\", \"Single lab, correlative pathway placement\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Uncovered a PI(3,4)P2 negative-feedback mechanism whereby accumulated PI(3,4)P2 inhibits PI3K and modulates PI3K-inhibitor sensitivity in PTEN-null TNBC.\",\n      \"evidence\": \"Knockdown/overexpression in PTEN-null TNBC lines with p-Akt Westerns and isoform-selective PI3K inhibitor assays\",\n      \"pmids\": [\"28196852\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular target of the inhibitory PI(3,4)P2 signal not identified\", \"Generalizability beyond PTEN-null context untested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Added IRF2 as an upstream transcriptional activator of INPP4B governing AML growth and apoptosis.\",\n      \"evidence\": \"IRF2 promoter binding, INPP4B rescue after IRF2 knockdown, colony formation and apoptosis assays\",\n      \"pmids\": [\"28579269\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct promoter occupancy via rigorous ChIP not detailed\", \"Downstream INPP4B effector in this axis unspecified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Confirmed that endosomal PI(3,4)P2-to-PI(3)P conversion by INPP4B drives SGK3-dependent survival in NPM1-mutant AML independent of Akt.\",\n      \"evidence\": \"Overexpression/knockdown, SGK3 knockdown rescue, PI(3,4)P2/PI(3)P ELISA, and ERK/Ets-1 analysis\",\n      \"pmids\": [\"29343273\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Subcellular site of lipid conversion not imaged\", \"How SGK3 promotes survival downstream not detailed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated that Inpp4b loss cooperates with SV40 T-Large to promote transformation via elevated p-Akt, but is insufficient alone, defining it as a context-dependent suppressor.\",\n      \"evidence\": \"MEF transformation assays with Inpp4b knockout/overexpression across oncogene combinations and p-Akt Westerns\",\n      \"pmids\": [\"31695845\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of cooperativity with T-Large not dissected\", \"Specific lipid substrate change not measured\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined the late-endosomal, Rab7-anchored pool of INPP4B that produces PI(3)P to drive lysosomal GSK3β degradation and oncogenic Wnt/β-catenin signaling in PIK3CA-mutant breast cancer.\",\n      \"evidence\": \"Integrated proteomics/imaging, Rab7 interaction, phosphoinositide measurement, GSK3β degradation, Wnt reporters, Hrs-depletion rescue, and in vivo growth\",\n      \"pmids\": [\"34035258\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of late- vs early-endosomal targeting incompletely defined\", \"Generalizability beyond PIK3CA-mutant ER+ breast cancer untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed INPP4B restrains endocytic PI(3,4)P2 to limit EGFR/MET recycling and signaling duration, with its loss amplifying both AKT and MEK/ERK in TNBC.\",\n      \"evidence\": \"INPP4B-knockout TNBC mouse model, phosphoinositide localization, RTK pulse-chase trafficking, and PI3K/MEK inhibitor sensitivity in vivo\",\n      \"pmids\": [\"32513774\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct adaptor linking INPP4B to specific RTK endosomes not identified\", \"Whether protein phosphatase activity contributes unaddressed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established that INPP4B is required for TGFβ receptor endocytosis and Smad2/3 activation through sequential phosphoinositide conversion with synaptojanin1 and PI3K-C2α.\",\n      \"evidence\": \"siRNA knockdown of pathway components, live-cell phosphoinositide imaging, receptor endocytosis and Smad phosphorylation assays\",\n      \"pmids\": [\"31913757\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct enzymatic ordering at the membrane inferred, not reconstituted\", \"Single-lab knockdown evidence\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified ERβ1 as an androgen-independent transcriptional inducer of INPP4B that suppresses Akt and migration in prostate cancer.\",\n      \"evidence\": \"ERβ1 engineering and ligand treatment in PC3 cells with INPP4B/p-Akt Westerns and migration assays\",\n      \"pmids\": [\"33020300\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ERβ1 promoter binding not shown\", \"In vivo relevance untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Extended INPP4B function to whole-body metabolism, showing it suppresses hepatic AKT/PKC and SREBP1 cleavage to maintain insulin sensitivity and restrain lipogenesis.\",\n      \"evidence\": \"Inpp4b knockout mice on high-fat diet with SREBP1 cleavage analysis, AKT/PKC Westerns, metabolic phenotyping, and histology\",\n      \"pmids\": [\"33772116\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic link between INPP4B and SREBP1 protease not defined\", \"Tissue-specific contributions not separated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed INPP4B's requirement for lysosomal homeostasis and autophagy by limiting VPS34-driven lysosomal PtdIns(3)P.\",\n      \"evidence\": \"Inpp4b-deficient MEFs with PIKfyve inhibition, lysosome imaging, HPLC PtdIns quantification, and VPS34 activity assays\",\n      \"pmids\": [\"35760104\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How INPP4B suppresses VPS34 activity mechanistically unclear\", \"Relationship to its own PI(3)P-generating activity not reconciled\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed INPP4B, distinct from PTEN, supports EZH2 expression and H3 methylation and engages a unique set of downstream effectors in prostate cells.\",\n      \"evidence\": \"Knockdown in prostate cancer lines and Inpp4b knockout mouse prostate analysis with EZH2/H3-methylation Westerns and scRNA-seq\",\n      \"pmids\": [\"38001678\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism connecting INPP4B to EZH2 unknown\", \"Correlative human data\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined a cell-intrinsic requirement for Inpp4b in B-1 cell maintenance and antibody responses, broadening its role in immune cell homeostasis.\",\n      \"evidence\": \"Conventional Inpp4b knockout mice, adoptive transfer, flow cytometry, and CD40-mediated B cell proliferation assays\",\n      \"pmids\": [\"37389566\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling pathway underlying B-1 defect not defined\", \"Whether phosphatase activity is required untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established INPP4B as a hallmark of tissue-resident ILC1s and intratumoral NK cells, required for their AKT-dependent survival and antitumor immunity.\",\n      \"evidence\": \"scRNA-seq, conditional Inpp4b knockout, apoptosis and AKT-phosphorylation assays, and intratumoral immune-cell and tumor-growth quantification\",\n      \"pmids\": [\"38197946\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a PI3K/AKT-suppressing phosphatase promotes AKT-dependent survival mechanistically unresolved\", \"Lipid substrate in this cell type not measured\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connected INPP4B to lysosomal exocytosis, showing it drives TRPML1-dependent FN1 secretion to promote PDAC migration and invasion.\",\n      \"evidence\": \"Overexpression/knockdown in PDAC cells, FN1 secretion assays, TRPML1 inhibition/knockdown, F-actin/FAK readouts, and invasion assays\",\n      \"pmids\": [\"40962057\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phosphoinositide intermediate linking INPP4B to TRPML1 not identified\", \"Single-lab study\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how a single phosphatase produces opposing tumor-suppressive (AKT-suppressing) and oncogenic (SGK3/Wnt-activating) outputs, and what molecular determinants direct its localization and substrate choice across cell types.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model linking localization to substrate selection\", \"Physiological protein phosphatase substrates unidentified\", \"Mechanism reconciling AKT suppression with AKT-dependent immune-cell survival unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [1, 2, 5, 11, 19]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [4, 11, 12]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [11, 19, 23]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 3, 5, 11]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [12, 13, 23]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [9, 18]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [20, 24]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [19]}\n    ],\n    \"complexes\": [\"BRCA1/ATM/ATR complex\"],\n    \"partners\": [\"Rab7\", \"ATR\", \"BRCA1\", \"SYNJ1\", \"PIK3C2A\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}